Glycerophosphocholine
Background and Biological Basis
Section titled “Background and Biological Basis”Glycerophosphocholine (GPC) is a naturally occurring choline compound that serves as a fundamental building block and signaling molecule within the human body. It is derived from phosphatidylcholine, a primary component of cellular membranes, through the action of phospholipases. As a lysophospholipid, GPC features a single fatty acid chain attached to its glycerol backbone, distinguishing it from diacylglycerophospholipids that possess two. GPC plays a crucial role as a readily available source of choline, which is essential for the synthesis of acetylcholine, a vital neurotransmitter, and for various metabolic processes, including lipid transport and cell membrane repair. It is also recognized as an intermediate in the complex pathways of phospholipid metabolism.
Clinical Relevance
Section titled “Clinical Relevance”Genetic variations have been shown to significantly influence the circulating levels of glycerophosphocholine and related metabolites. A genome-wide association study identified robust associations between single nucleotide polymorphisms (SNPs) within theFADS1gene and the concentrations of various glycerophospholipids, including lyso-phosphatidylcholine derivatives such as PC a C20:4, which is a form of glycerophosphocholine.[1] The FADS1 gene is responsible for encoding fatty acid delta-5 desaturase, an enzyme critical for the metabolism of long-chain polyunsaturated omega-3 and omega-6 fatty acids. Research indicates that a specific genetic variant, rs174548 , located in a region of linkage disequilibrium encompassing the FADS1 gene, is strongly associated with these metabolite levels. Individuals carrying the minor allele of rs174548 exhibit reduced efficiency of the fatty acid delta-5 desaturase enzyme, leading to lower concentrations of arachidonic acid and its lyso-phosphatidylcholine derivative (PC a C20:4).[1] This particular SNP has been found to account for up to 10% of the observed variance in the levels of certain glycerophospholipids.[1]Such genetic influences underscore the importance of glycerophosphocholine as a “metabotype” that reflects an individual’s unique genetic profile.
Social Importance
Section titled “Social Importance”The identification of genetic factors that influence glycerophosphocholine levels holds substantial implications for advancing personalized health and medicine. Given its integral role in fatty acid metabolism, the structural integrity of cell membranes, and the availability of choline, variations in GPC levels can impact a wide array of physiological functions and potentially affect an individual’s predisposition to various metabolic conditions. The capacity to link specific genetic variants to distinct metabolic profiles, such as those involving glycerophosphocholine, enhances our understanding of human health, disease pathogenesis, and provides avenues for developing tailored nutritional interventions or therapeutic strategies that are customized to an individual’s unique genetic and metabolic characteristics.
Methodological Scope and Statistical Robustness
Section titled “Methodological Scope and Statistical Robustness”The identification of genetic variants associated with glycerophosphocholine levels is inherently constrained by the statistical power of the contributing genome-wide association studies (GWAS). While meta-analyses were employed to boost sample sizes, the possibility remains that additional sequence variants with smaller effects could be discovered with even larger cohorts, thereby increasing the overall statistical power for gene discovery.[2]This limitation suggests that the current understanding of the genetic architecture influencing glycerophosphocholine levels may not be exhaustive, potentially overlooking subtle yet significant genetic contributions.
Furthermore, the robust validation of identified associations is a critical hurdle, as “replication in an independent population is the gold standard of all GWA studies”.[1] Although some studies attempted replication across multiple cohorts.[2] the “ultimate validation” extends beyond statistical replication to include functional studies that elucidate the biological mechanisms.[3]Without comprehensive functional characterization, the precise role of many associated genetic variants in modulating glycerophosphocholine metabolism remains a significant knowledge gap, impacting the translation of these findings into clinical or biological insights. The challenge of “sorting through associations and prioritizing SNPs for follow-up” underscores the need for more systematic approaches to move from statistical correlation to causal understanding.[3]
Generalizability Across Populations and Phenotype Specificity
Section titled “Generalizability Across Populations and Phenotype Specificity”A significant limitation for the broader applicability of findings related to glycerophosphocholine is the predominant focus on populations of European ancestry in many of the foundational studies.[2] Genetic associations and their effect sizes can vary substantially across different ancestral groups due to differences in allele frequencies, linkage disequilibrium structures, and environmental exposures.[4] Although efforts were made to extend findings to multiethnic cohorts.[5] the generalizability of these genetic insights to a global population remains incomplete, necessitating further research in diverse ethnic groups.
The precise definition and measurement of glycerophosphocholine phenotypes also present considerations. While careful adjustments for covariates such as age, sex, and ancestry-informative principal components were performed to derive standardized residual lipid concentrations.[2] the use of metabolite concentrations as “proxies for clinical parameters”.[1] though powerful, might not always fully capture the direct clinical relevance or the multifaceted nature of the underlying biological processes. Furthermore, while most studies excluded individuals on lipid-lowering therapy.[2]historical cohorts where this was not feasible could introduce subtle confounders, potentially influencing the observed genetic associations with glycerophosphocholine levels.
Unraveling Underlying Biological Mechanisms
Section titled “Unraveling Underlying Biological Mechanisms”The current understanding of glycerophosphocholine genetics largely focuses on identifying statistical associations between single nucleotide polymorphisms and metabolite levels. While studies have begun to offer “new insights into the underlying biochemical mechanism” by linking variants in genes likeFADS1 and LIPC to specific metabolic pathways.[1]the comprehensive elucidation of the entire biological cascade from genetic variation to altered glycerophosphocholine concentrations remains an ongoing challenge. The complex interplay of gene regulation, enzymatic activity, and downstream metabolic processes requires further functional characterization beyond initial GWAS findings.
Furthermore, the potential influence of environmental factors and gene-environment interactions on glycerophosphocholine levels is an area that warrants more focused investigation. Although studies adjust for basic demographic variables like age and sex.[2]the impact of specific dietary patterns, lifestyle choices, or other unmeasured environmental confounders on the observed genetic associations is not extensively detailed within the available research. A more thorough exploration of these complex interactions is crucial to fully understand the phenotypic variability of glycerophosphocholine and to develop more precise predictive or therapeutic strategies.
Variants
Section titled “Variants”Genetic variations can influence a wide array of metabolic processes, including the synthesis and breakdown of glycerophosphocholine, a crucial phospholipid metabolite involved in cell membrane structure and signaling. The genes_LINC02096_ and _CDRT7_, along with the variant *rs9892299 *, are implicated in cellular regulation that can indirectly affect lipid homeostasis. _LINC02096_ is a long non-coding RNA, often involved in regulating gene expression, which can impact metabolic pathways through epigenetic mechanisms or transcriptional control. _CDRT7_plays a role in cilia function, and cilia are essential organelles that mediate various cellular signaling pathways, thereby modulating metabolic states and lipid processing within cells. A single nucleotide polymorphism (SNP) like*rs9892299 *, depending on its location, could alter regulatory elements or gene coding sequences, potentially affecting the efficiency of enzymes or transporters critical for lipid metabolism, including those related to glycerophosphocholine. Such alterations can lead to subtle shifts in the balance of lipid synthesis, degradation, or transport, influencing the overall glycerophosphocholine profile.[1] These genetic variations can collectively contribute to an individual’s unique metabolic landscape.
Further, _LSAMP_, _SIDT1_, and the variants *rs1347055 * and *rs17325765 * also contribute to the complex genetic architecture underlying metabolic traits. _LSAMP_ (Limbic System-Associated Membrane Protein) is primarily known for its role in neuronal development and function, particularly within the limbic system, and while not directly involved in lipid metabolism, neurological processes can broadly influence systemic metabolic regulation. _SIDT1_ (SID1 Transmembrane Family Member 1) is involved in the cellular uptake and regulation of RNA, a fundamental process that impacts the expression of enzymes and proteins critical for lipid synthesis and catabolism. A genetic variant such as *rs1347055 * or *rs17325765 *could potentially modify the function or expression of these genes, leading to changes in the cellular environment that, in turn, affect the levels of glycerophosphocholine. Any alterations in RNA regulation or cellular signaling, mediated by these genes and variants, could result in an imbalance in phospholipid homeostasis, impacting membrane integrity and cell signaling.[6] The pseudogenes _SLC25A38P1_ and _AIMP1P2_, along with the variant *rs859722 *, represent additional genetic factors with potential metabolic implications. _SLC25A38P1_ is a pseudogene related to _SLC25A38_, a gene involved in mitochondrial glycine transport, highlighting its connection to mitochondrial function, which is central to energy metabolism and lipid oxidation. While pseudogenes are often considered non-coding, some can exert regulatory roles, influencing the expression of their functional counterparts or other metabolic genes, thereby impacting the catabolism and availability of lipids. Similarly,_AIMP1P2_ is a pseudogene of _AIMP1_, which is involved in protein synthesis and possesses cytokine-like activities. Variations within these pseudogenes or a SNP like*rs859722 *could subtly affect protein synthesis efficiency or signaling pathways that modulate lipid metabolism, thereby influencing the intricate balance of glycerophosphocholine production and utilization.[1]These genetic factors underscore the complex interplay of cellular processes that ultimately determine the levels of critical metabolites like glycerophosphocholine, which is vital for membrane biogenesis and lipid signaling.[6]
Key Variants
Section titled “Key Variants”Defining Glycerophosphocholines and Their Subtypes
Section titled “Defining Glycerophosphocholines and Their Subtypes”Glycerophosphocholines represent a significant class of glycerophospholipids, which are fundamental components of biological membranes and crucial signaling molecules. Within this broader category, specific subtypes are distinguished by their structural composition and the nature of their fatty acid attachments to the glycerol backbone. A prominent example is phosphatidylcholine (PC), which can be further classified based on the presence of ester or ether bonds in its glycerol moiety. For instance, “diacyl” (aa) indicates two fatty acid residues attached via ester bonds, while “acyl-alkyl” (ae) signifies one acyl and one alkyl chain, and “dialkyl” (ee) denotes two alkyl chains. A single letter (a for acyl or e for alkyl) indicates the presence of a single fatty acid residue, as seen in lyso-phosphatidylcholine derivatives like PC a C20:4.[1] These structural variations contribute to the diverse biological roles and metabolic fates of glycerophosphocholines.
Nomenclature and Structural Classification Systems
Section titled “Nomenclature and Structural Classification Systems”The nomenclature for glycerophosphocholines and related lipids employs standardized abbreviations to convey structural details. For example, “PC ae C33:1” denotes a plasmalogen/plasmenogen phosphatidylcholine, where “ae” specifies the acyl-alkyl bond configuration, “C33” indicates a total of 33 carbons across its two fatty acid side chains, and “:1” signifies the presence of one double bond within these side chains.[1] This detailed notation allows for precise communication of lipid structures, although the exact positions of double bonds and the distribution of carbon atoms in individual fatty acid side chains cannot always be determined by certain analytical technologies. Furthermore, stereochemical differences or isobaric fragments can sometimes lead to ambiguity in mapping metabolite names to individual masses, necessitating careful interpretation and, in some cases, indicating possible alternative assignments.[1]
Measurement Approaches and Clinical Significance
Section titled “Measurement Approaches and Clinical Significance”The measurement of glycerophosphocholine concentrations is typically achieved through targeted quantitative metabolomics platforms, such as electrospray ionization (ESI) tandem mass spectrometry (MS/MS).[1] This technology allows for the determination of fasting serum concentrations of numerous endogenous metabolites, including various phosphatidylcholines and plasmalogen/plasmenogen phosphatidylcholines. These measurements are critical for genome-wide association (GWA) studies, where glycerophosphocholines serve as metabolic traits or “proxies” for clinical parameters like blood cholesterol levels.[1] Genetic variants, such as those in the FADS1gene, can significantly influence the concentrations of specific glycerophosphocholines, including arachidonic acid and its lyso-phosphatidylcholine derivative (PC a C20:4), highlighting their role in metabolic pathways and their potential as biomarkers for understanding complex metabolic diseases.[1]
Biological Background of Glycerophosphocholine
Section titled “Biological Background of Glycerophosphocholine”Glycerophosphocholine (GPC), specifically phosphatidylcholine (PC), is a fundamental glycerophospholipid that plays a vital role in cellular structure and metabolism. As a key component of cellular membranes, its synthesis and regulation are integral to maintaining lipid homeostasis within the body. Variations in the levels and composition of glycerophosphocholine species are often linked to genetic factors and can reflect broader metabolic states.
Glycerophosphocholine Synthesis and Lipid Metabolism
Section titled “Glycerophosphocholine Synthesis and Lipid Metabolism”The biosynthesis of glycerophosphocholines, a major class of phospholipids, primarily occurs through the Kennedy pathway. This process involves the sequential addition of two fatty acid moieties to a glycerol 3-phosphate backbone, followed by dephosphorylation and the subsequent attachment of a phosphocholine group.[1] The specific fatty acid chains incorporated into glycerophosphocholines are crucial for their function and are often derived from essential fatty acids, such as linoleic acid (C18:2), which are elongated and desaturated through metabolic pathways.[1] Key enzymes like fatty acid desaturases (FADS) are instrumental in this process; for instance, FADS1 catalyzes the delta-5 desaturation, converting eicosatrienoyl-CoA (C20:3) into arachidonyl-CoA (C20:4), which is then incorporated into various glycerophospholipids, including specific phosphatidylcholines like PC aa C36:4.[1] The balance between different fatty acid species, influenced by enzymes such as FADS1, directly impacts the types and concentrations of glycerophosphocholines produced. For example, PC aa C36:4 and PC aa C36:3 can be considered products and modified substrates of the delta-5 desaturase reaction, respectively, highlighting the dynamic nature of these metabolic interconversions.[1]This intricate metabolic network also extends to other glycerophospholipid species, including phosphatidic acids (PA), phosphatidylethanolamines (PE), phosphatidylglycerols (PG), phosphatidylinositols (PI), phosphatidylinositol-bisphosphates (PIP2), and phosphatidylserines (PS), all contributing to the diverse lipid landscape of cells.[1]
Molecular Structure and Cellular Roles
Section titled “Molecular Structure and Cellular Roles”Glycerophosphocholines are characterized by their glycerol backbone, to which fatty acid residues and a phosphocholine head group are attached. These lipids are further differentiated by the type of bonds present in the glycerol moiety, such as diacyl (aa), acyl-alkyl (ae), or dialkyl (ee) bonds, and by the specific composition of their fatty acid side chains, denoted by the total number of carbons and double bonds (e.g., Cx:y).[1]This structural diversity allows for a wide array of glycerophosphocholine species, each potentially having specialized roles within the cell. Their primary cellular function is to serve as fundamental building blocks for biological membranes, contributing to membrane fluidity, integrity, and various signaling processes.[6] For instance, lyso-phosphatidylcholine PC a C20:4, formed from a single arachidonyl moiety, represents another functional form of this critical lipid.[1]
Genetic Influence on Glycerophosphocholine Levels
Section titled “Genetic Influence on Glycerophosphocholine Levels”Genetic variations significantly impact the circulating levels of glycerophosphocholines and related lipids. A notable example is the single nucleotide polymorphism (SNP)rs174548 located within the FADS1gene cluster, which is strongly associated with the concentrations of several glycerophosphocholine species.[1] Individuals carrying the minor allele of rs174548 typically exhibit lower concentrations of polyunsaturated glycerophosphocholines, such as PC aa C36:4, PC aa C36:5, PC aa C38:4, and their lyso-phosphatidylcholine derivative PC a C20:4, as well as reduced levels of arachidonic acid (C20:4).[1]This suggests that the polymorphism may impair the catalytic activity or reduce the protein abundance of the FADS1 enzyme, thereby altering the availability of specific fatty acids required for glycerophosphocholine synthesis.[1] The ratio of product-to-substrate concentrations, such as [PC aa C36:4]/[PC aa C36:3], serves as a robust indicator of the FADS1 enzyme’s efficiency, with genetic variants in this region explaining a substantial portion of the population’s variance in these metabolite levels.[1]
Systemic Implications and Metabolic Interactions
Section titled “Systemic Implications and Metabolic Interactions”The synthesis and regulation of glycerophosphocholines are deeply integrated into the broader lipid metabolism of the body, affecting systemic lipid profiles and cellular functions across various tissues. Enzymes like lecithin-cholesterol acyltransferase (LCAT), which acts on lecithin (phosphatidylcholine), are crucial for cholesterol esterification and high-density lipoprotein (HDL) metabolism, with deficiencies leading to specific lipid disorders.[7] Furthermore, other key biomolecules and pathways involved in lipid regulation, such as 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which is targeted by cholesterol-lowering drugs, and apolipoprotein CIII (APOC3), which influences triglyceride metabolism, demonstrate the complex interplay surrounding glycerophosphocholine.[4] Disruptions in these pathways, often influenced by genetic variants in genes like ANGPTL3 and ANGPTL4, can lead to conditions such as dyslipidemia and may contribute to the risk of cardiovascular diseases.[8] The coordinated function of these molecular and cellular pathways, involving various proteins, enzymes, and genetic regulatory elements, is essential for maintaining lipid homeostasis and overall metabolic health.
Phospholipid Biosynthesis and Fatty Acid Metabolism
Section titled “Phospholipid Biosynthesis and Fatty Acid Metabolism”Glycerophosphocholine, as a key component of cellular membranes and a signaling molecule, is intimately linked to the broader metabolic pathways of phospholipids and fatty acids. Phosphatidylcholines (PC), which are direct precursors or derivatives of glycerophosphocholine, are primarily synthesized via the Kennedy pathway.[1]This pathway involves the sequential attachment of two fatty acid moieties to glycerol 3-phosphate, followed by a dephosphorylation step and the subsequent addition of a phosphocholine moiety.[1]The diversity of fatty acid side chains incorporated into phosphatidylcholines is crucial for membrane fluidity and function, with long-chain poly-unsaturated fatty acids (LCPUFAs) being derived from essential fatty acids like linoleic acid (C18:2) and alpha-linolenic acid (C18:3) through the omega-6 and omega-3 fatty acid synthesis pathways, respectively.[1]De novo synthesis within the human body can also produce un- and monosaturated fatty acids such as palmitic acid (C16:0), stearic acid (C18:0), and oleic acid (C18:1).[1] The FADS1 gene, located within the FADS1-FADS2 gene cluster, plays a significant role in the synthesis of these LCPUFAs, influencing the overall fatty acid composition of phospholipids.[9]
Regulation of Lipid Homeostasis
Section titled “Regulation of Lipid Homeostasis”The intricate balance of glycerophosphocholine and related lipids is maintained through various regulatory mechanisms, including gene expression, protein modification, and allosteric control. A central regulatory point in lipid metabolism is the mevalonate pathway, which is controlled by 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR).[10] The activity of HMGCR is subject to regulation, and common genetic variations (SNPs) in the HMGCR gene can impact its function, specifically by affecting the alternative splicing of exon 13, which in turn influences LDL-cholesterol levels.[11] Beyond direct enzymatic control, transcriptional regulation plays a vital role; for instance, hepatocyte nuclear factor 4alpha (HNF4A) is essential for the maintenance of hepatic gene expression and overall lipid homeostasis.[12] Similarly, hepatocyte nuclear factor-1alpha (HNF1A) is identified as a critical regulator of bile acid and plasma cholesterol metabolism, underscoring the hierarchical control of lipid pathways.[13] Furthermore, sterol regulatory element-binding protein 2 (SREBP-2) is known to regulate isoprenoid and adenosylcobalamin metabolism, indicating broader regulatory integration across different metabolic branches.[14]
Systemic Lipid Transport and Inter-Pathway Crosstalk
Section titled “Systemic Lipid Transport and Inter-Pathway Crosstalk”The metabolism of glycerophosphocholine and its derivatives is not isolated but is part of a complex network of interacting pathways that govern systemic lipid transport and overall metabolic homeostasis. Enzymes like lecithin:cholesterol acyltransferase (LCAT), which uses fatty acids from lecithin (a phosphatidylcholine) to esterify cholesterol, are crucial for cholesterol transport and maturation of high-density lipoproteins (HDL).[7] Dysfunctions in LCAT activity lead to distinct deficiency syndromes.[7] Plasma phospholipid transfer protein (PLTP) also plays a significant role in lipid remodeling by influencing HDL levels.[15] Beyond these, angiopoietin-like protein 3 (ANGPTL3) and angiopoietin-like protein 4 (ANGPTL4) are key regulators of lipid metabolism, with ANGPTL4 specifically known to reduce triglycerides and increase HDL.[8] These interactions highlight a systemic integration where alterations in one component can ripple through the entire lipid transport and metabolic network. Signaling cascades, such as the one involving phosphodiesterase 5A (PDE5A), which is increased by Angiotensin II in vascular smooth muscle cells to antagonize cGMP signaling, also underscore the crosstalk between metabolic regulation and cellular signaling.[16]
Disease Implications of Glycerophosphocholine Metabolism
Section titled “Disease Implications of Glycerophosphocholine Metabolism”Dysregulation within the pathways governing glycerophosphocholine and related lipid metabolism is frequently implicated in the etiology and progression of various diseases. For instance, common genetic variants at numerous loci contribute to polygenic dyslipidemia, reflecting widespread pathway dysregulation.[2]Hypertriglyceridemia, a common lipid disorder, has been linked to mechanisms such as diminished very low-density lipoprotein (VLDL) fractional catabolic rate, associated with increased apolipoprotein CIII (APOC3) and reduced apolipoprotein E (APOE) on lipid particles.[17]Non-alcoholic Fatty Liver Disease (NAFLD) involves specific enzymes like glycosylphosphatidylinositol-specific phospholipase D, indicating a role for phospholipase activity in liver pathology.[18]Furthermore, cholestatic hypercholesterolemia is associated with the uptake of lipoprotein-X and its impact onHMGCR activity.[19]while gallstone disease has been linked to the hepatic cholesterol transporterABCG8.[20]Metabolomics studies also reveal distinct metabolic phenotypes in conditions like diabetes, where therapeutic interventions can alter metabolite profiles.[21]Even seemingly distant pathways, such as uric acid metabolism, influenced by the urate transporterSLC2A9 (GLUT9), can reflect broader metabolic health and disease susceptibility.[22]
Genetic Determinants of Glycerophosphocholine Levels
Section titled “Genetic Determinants of Glycerophosphocholine Levels”Glycerophosphocholine, as a component of the broader class of glycerophospholipids and phosphatidylcholines, is a metabolic trait whose circulating levels can be influenced by genetic variations. Genome-wide association studies (GWAS) have identified specific genetic loci that correlate with the concentrations of these endogenous organic compounds in human serum. For instance, the minor allele ofrs174548 has been associated with lower concentrations of numerous phosphatidylcholines, particularly those with four or more double bonds in their polyunsaturated fatty acid (PUFA) side chains, and reduced levels of arachidonic acid and its lyso-phosphatidylcholine derivative.[1] This genetic link suggests that variants, such as those near the FADS1 gene, play a role in regulating the metabolism of these crucial phospholipids, thereby impacting overall lipid profiles. Understanding these genetic determinants can provide insights into fundamental metabolic pathways and their perturbations in various health conditions.[1]
Biomarker Potential in Metabolic and Cardiovascular Health
Section titled “Biomarker Potential in Metabolic and Cardiovascular Health”The concentrations of glycerophosphocholine and related phosphatidylcholines hold potential as biomarkers for assessing metabolic health and cardiovascular risk. As components of lipid profiles, these metabolites can serve as proxies for established clinical parameters, including blood cholesterol levels.[1]Deviations in their serum concentrations, particularly those influenced by genetic factors, may indicate an altered metabolic state or increased susceptibility to dyslipidemia. Such insights could contribute to improved diagnostic utility and risk assessment strategies, allowing clinicians to identify individuals at higher risk for metabolic syndrome, cardiovascular disease, and associated complications. Monitoring these phospholipid levels, especially in conjunction with genetic information, could offer a more comprehensive view of a patient’s metabolic landscape and guide early intervention.[1]
Personalized Risk Stratification and Prevention
Section titled “Personalized Risk Stratification and Prevention”Integrating genetic information with glycerophosphocholine levels can enhance personalized medicine approaches, particularly in risk stratification and the development of targeted prevention strategies. By identifying individuals who carry genetic variants associated with unfavorable glycerophosphocholine profiles, clinicians may be able to predict long-term outcomes, disease progression, or even differential responses to interventions. This personalized approach moves beyond traditional risk factors, leveraging an individual’s unique genetic and metabolic signature to pinpoint those at high risk for developing conditions like dyslipidemia and its cardiovascular sequelae. Ultimately, this could lead to more precise prevention strategies, including tailored dietary recommendations or pharmacological interventions, aimed at modulating glycerophosphocholine metabolism to improve patient care.[1]
References
Section titled “References”[1] Gieger C, et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet (2008): PMID: 19043545.
[2] Kathiresan S, et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet (2008): PMID: 19060906.
[3] Benjamin EJ, et al. Genome-wide association with select biomarker traits in the Framingham Heart Study. BMC Med Genet. 2007;8:64.
[4] Burkhardt R, et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol (2008): PMID: 18802019.
[5] Willer, C.J., et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nat Genet, vol. 40, no. 2, 2008, pp. 161–169.
[6] Vance JE. “Membrane lipid biosynthesis.” Encyclopedia of Life Sciences: John Wiley & Sons, Ltd: Chichester (2001).
[7] Kuivenhoven JA, et al. “The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.” J Lipid Res 38 (1997): 191–205.
[8] Koishi R, et al. “Angptl3 regulates lipid metabolism in mice.” Nat Genet 30 (2002): 151–157.
[9] Schaeffer L, et al. “Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids.” Hum Mol Genet 15 (2006): 1745–1756.
[10] Goldstein JL, Brown MS. “Regulation of the mevalonate pathway.” Nature 343 (1990): 425–430.
[11] Edwards PA, Lemongello D, Fogelman AM. “Improved methods for the solubilization and assay of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase.” J Lipid Res 20 (1979): 40–46.
[12] Hayhurst GP, et al. “Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis.” Mol Cell Biol 21 (2001): 1393–1403.
[13] Shih DQ, et al. “Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism.” Nat Genet 27 (2001): 375–382.
[14] Murphy C, et al. “Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism.” Biochem Biophys Res Commun 355 (2007): 359–364.
[15] Jiang XC, et al. “Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels.”J Clin Invest 103 (1999): 907–914.
[16] Kim D, et al. “Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling.”J Mol Cell Cardiol 38 (2005): 175–184.
[17] Aalto-Setala K, et al. “Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.”J Clin Invest 90 (1992): 1889–1900.
[18] Chalasani N, et al. “Glycosylphosphatidylinositol-specific phospholipase d in nonalcoholic Fatty liver disease: A preliminary study.”J Clin Endocrinol Metab 91 (2006): 2279–2285.
[19] Walli AK, Seidel D. “Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and…”J Clin Invest 74 (1984): 867–879.
[20] Buch S, et al. “A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease.”Nat Genet 39 (2007): 995–999.
[21] Altmaier E, et al. “Bioinformatics analysis of targeted metabolomics - uncovering old and new tales of diabetic mice under medication.” Endocrinology 149 (2008): 3478–3489.
[22] Do¨ring A, et al. “SLC2A9 influences uric acid concentrations with pronounced sex-specific effects.”Nat Genet 40 (2008): 430–436.